EP3532604A4 - Method for increasing cell proliferation in pancreatic beta cells, treatment method and composition - Google Patents
Method for increasing cell proliferation in pancreatic beta cells, treatment method and composition Download PDFInfo
- Publication number
- EP3532604A4 EP3532604A4 EP17863636.1A EP17863636A EP3532604A4 EP 3532604 A4 EP3532604 A4 EP 3532604A4 EP 17863636 A EP17863636 A EP 17863636A EP 3532604 A4 EP3532604 A4 EP 3532604A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- cell proliferation
- beta cells
- pancreatic beta
- increasing cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662413071P | 2016-10-26 | 2016-10-26 | |
PCT/US2017/058498 WO2018081401A1 (en) | 2016-10-26 | 2017-10-26 | Method for increasing cell proliferation in pancreatic beta cells, treatmen t method.and composition |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3532604A1 EP3532604A1 (en) | 2019-09-04 |
EP3532604A4 true EP3532604A4 (en) | 2020-06-03 |
Family
ID=62025476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17863636.1A Withdrawn EP3532604A4 (en) | 2016-10-26 | 2017-10-26 | Method for increasing cell proliferation in pancreatic beta cells, treatment method and composition |
Country Status (5)
Country | Link |
---|---|
US (1) | US11266647B2 (en) |
EP (1) | EP3532604A4 (en) |
JP (1) | JP2019531753A (en) |
CA (1) | CA3039220A1 (en) |
WO (1) | WO2018081401A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021503486A (en) | 2017-11-20 | 2021-02-12 | アイカーン スクール オブ メディシン アット マウント サイナイ | Kinase Inhibitor Compounds and Compositions and Usage |
US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
US11866427B2 (en) | 2018-03-20 | 2024-01-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013119518A1 (en) * | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Small molecules for islet expansion |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL375979A1 (en) * | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
CA2513086A1 (en) * | 2002-12-19 | 2004-07-08 | Scios Inc. | Treatment of obesity and associated conditions with tgf-.beta. inhibitors |
WO2009114180A1 (en) * | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
WO2010080756A2 (en) * | 2009-01-06 | 2010-07-15 | Osteogenex, Inc. | Harmine derivatives for reducing body weight |
US20110123651A1 (en) * | 2009-05-20 | 2011-05-26 | Mower Thomas E | Dietary supplement drink for delivery of resveratrol and other polyphenols |
RU2576000C2 (en) * | 2010-08-09 | 2016-02-27 | Такеда Фармасьютикал Компани Лимитед | Method for preparing pancreatic hormone-producing cells |
JPWO2014058080A1 (en) | 2012-11-30 | 2016-09-05 | 国立研究開発法人理化学研究所 | Method for enhancing reprogramming of somatic cells and cell preparation kit |
US10233170B2 (en) | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
WO2016100909A1 (en) * | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
WO2017168245A1 (en) | 2016-04-01 | 2017-10-05 | University Of Limerick | Pharmaceutical compositions and methods for the treatment of diabetes |
-
2017
- 2017-10-26 JP JP2019522511A patent/JP2019531753A/en active Pending
- 2017-10-26 US US16/344,230 patent/US11266647B2/en active Active
- 2017-10-26 WO PCT/US2017/058498 patent/WO2018081401A1/en unknown
- 2017-10-26 EP EP17863636.1A patent/EP3532604A4/en not_active Withdrawn
- 2017-10-26 CA CA3039220A patent/CA3039220A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013119518A1 (en) * | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Small molecules for islet expansion |
Non-Patent Citations (8)
Title |
---|
JANIS VOGT ET AL: "The specificities of small molecule inhibitors of the TGFÃ and BMP pathways", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 23, no. 11, 21 June 2011 (2011-06-21), pages 1831 - 1842, XP028261454, ISSN: 0898-6568, [retrieved on 20110629], DOI: 10.1016/J.CELLSIG.2011.06.019 * |
PENG WANG ET AL: "A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication", NATURE MEDICINE, vol. 21, no. 4, 9 March 2015 (2015-03-09), New York, pages 383 - 388, XP055388866, ISSN: 1078-8956, DOI: 10.1038/nm.3820 * |
PENG WANG ET AL: "Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells", CELL METABOLISM, vol. 29, no. 3, 1 March 2019 (2019-03-01), United States, pages 638 - 652.e5, XP055688667, ISSN: 1550-4131, DOI: 10.1016/j.cmet.2018.12.005 * |
ROSADO-OLIVIERI EDWIN A ET AL: "Identification of a LIF-Responsive, Replication-Competent Subpopulation of Human [beta] Cells", CELL METABOLISM, CELL PRESS, UNITED STATES, vol. 31, no. 2, 9 January 2020 (2020-01-09), pages 327, XP086013512, ISSN: 1550-4131, [retrieved on 20200109], DOI: 10.1016/J.CMET.2019.12.009 * |
SANGEETA DHAWAN ET AL: "Inhibition of TGF-[Beta] Signaling Promotes Human Pancreatic [Beta]-Cell Replication", DIABETES, 1 May 2016 (2016-05-01), New York, pages 1208, XP055501778, Retrieved from the Internet <URL:http://diabetes.diabetesjournals.org/content/diabetes/early/2016/02/26/db15-1331.full.pdf> * |
See also references of WO2018081401A1 * |
VEDAVATHI MADHU ET AL: "Dual Inhibition of Activin/Nodal/TGF- [beta] and BMP Signaling Pathways by SB431542 and Dorsomorphin Induces Neuronal Differentiation of Human Adipose Derived Stem Cells", STEM CELLS INTERNATIONAL, vol. 2016, 20 December 2015 (2015-12-20), US, pages 1 - 13, XP055689013, ISSN: 1687-966X, DOI: 10.1155/2016/1035374 * |
WEIJUN SHEN ET AL: "Inhibition of DYRK1A and GSK3B induces human β-cell proliferation", NATURE COMMUNICATIONS, vol. 6, 26 October 2015 (2015-10-26), pages 8372, XP055409422, ISSN: 2041-1723, DOI: 10.1038/ncomms9372 * |
Also Published As
Publication number | Publication date |
---|---|
US20190328738A1 (en) | 2019-10-31 |
EP3532604A1 (en) | 2019-09-04 |
WO2018081401A8 (en) | 2019-05-02 |
JP2019531753A (en) | 2019-11-07 |
US11266647B2 (en) | 2022-03-08 |
WO2018081401A1 (en) | 2018-05-03 |
CA3039220A1 (en) | 2018-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3701041A4 (en) | Methods and compositions for treating diseases associated with exhausted t cells | |
EP3328404A4 (en) | Methods and compositions for producing pancreatic beta cells | |
EP3331582A4 (en) | Methods and compositions for treating cells for transplant | |
EP3390694A4 (en) | Method and system for efficiently operating electrochemical cells | |
EP3418376A4 (en) | Cell culture medium, culture method, and organoid | |
EP3369810A4 (en) | Method for producing cell population that includes mesenchymal stem cells, mesenchymal stem cells, cell population, and pharmaceutical composition | |
EP3636753A4 (en) | Method for manufacturing dna-edited eukaryotic cell, and kit used in method | |
EP3312268A4 (en) | Cell culture method, jig for cell culture, and cell culture device | |
EP3666887A4 (en) | Method for activating t cells for cancer treatment | |
EP3521419A4 (en) | Method for producing somatic cell, somatic cell, and composition | |
EP3384038A4 (en) | Methods and compositions for reprogramming cells | |
EP3325698A4 (en) | Cell culture, transport and investigation | |
EP3342858A4 (en) | Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells | |
EP3252141A4 (en) | Cell culturing method and kit | |
EP3735419A4 (en) | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | |
EP3630135A4 (en) | Compositions and methods for providing cell replacement therapy | |
EP3417061A4 (en) | Methods and compositions for gene editing in stem cells | |
EP3576187A4 (en) | Electrode composition, electrode, production method for said electrode, and battery | |
EP3515862A4 (en) | Electrochemical cells and methods for making same | |
EP3518582A4 (en) | Method for terminal to perform cell re-selection procedure, and device supporting same | |
GB2562920B (en) | Devices, methods, and compositions for restricting cell position and stabilizing cells in culture systems | |
EP3532604A4 (en) | Method for increasing cell proliferation in pancreatic beta cells, treatment method and composition | |
EP3309882A4 (en) | Cathode composition, cathode and fuel cell including same | |
EP3291287A4 (en) | Roller type solar cell sintering and irradiation annealing integrated continuous furnace | |
IL273805A (en) | Compositions and methods for treating diffuse large b cell lymphoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190520 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200506 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 35/39 20150101ALI20200428BHEP Ipc: A61K 9/50 20060101ALI20200428BHEP Ipc: C12N 5/071 20100101AFI20200428BHEP Ipc: A61P 3/10 20060101ALI20200428BHEP Ipc: A61K 9/20 20060101ALI20200428BHEP Ipc: A61K 31/4164 20060101ALI20200428BHEP Ipc: A61P 1/18 20060101ALI20200428BHEP Ipc: A61K 31/36 20060101ALI20200428BHEP Ipc: A61K 31/4178 20060101ALI20200428BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210112 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230222 |